S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer

Int J Mol Sci. 2018 Dec 19;19(12):4122. doi: 10.3390/ijms19124122.


S100A10, which is also known as p11, is located in the plasma membrane and forms a heterotetramer with annexin A2. The heterotetramer, comprising of two subunits of annexin A2 and S100A10, activates the plasminogen activation pathway, which is involved in cellular repair of normal tissues. Increased expression of annexin A2 and S100A10 in cancer cells leads to increased levels of plasmin-which promotes the degradation of the extracellular matrix-increased angiogenesis, and the invasion of the surrounding organs. Although many studies have investigated the functional role of annexin A2 in cancer cells, including ovarian cancer, S100A10 has been less studied. We recently demonstrated that high stromal annexin A2 and high cytoplasmic S100A10 expression is associated with a 3.4-fold increased risk of progression and 7.9-fold risk of death in ovarian cancer patients. Other studies have linked S100A10 with multidrug resistance in ovarian cancer; however, no functional studies to date have been performed in ovarian cancer cells. This article reviews the current understanding of S100A10 function in cancer with a particular focus on ovarian cancer.

Keywords: S100A10; annexin A2; chemotherapy resistance; ovarian cancer; plasmin.

Publication types

  • Review

MeSH terms

  • Annexin A2 / metabolism
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Ovarian Neoplasms / metabolism*
  • Protein Binding
  • S100 Proteins / chemistry*
  • S100 Proteins / metabolism*


  • Annexin A2
  • S100 Proteins